A patient treated with atexolizumab may develop an autoimmune keratitis.
Atexolizumab is a monoclonal protein that blocks interaction of PD-L1 with PD-1 and CD80 receptors.
Clinical features - bilateral presence of:
(1) ocular pain
(2) ocular erythema
(3) tearing
(4) photophobia
(5) blurring of vision
Slit-lamp exam shows corneal damage consistent with keratitis.
The diagnosis requires exclusion of other causes of keratitis.
The keratitis responds to discontinuation of atexolizumab therapy and/or therapy with corticosteroids.
To read more or access our algorithms and calculators, please log in or register.
Specialty: Hematology Oncology
